sero19A strains circulating are also resistant to multiple antimicrobial agents, making them difficult to treat. Six years after the introduction of PCV7, sero19A is the most common invasive pneumococcal serotype in the United States, with a substantial proportion of its strains being antimicrobial resistant [9] .
Although the serotype designation is important for understanding pneumococcal epidemiology, to gain a deeper perspective of the pneumococci circulating globally, a technique termed multilocus sequence typing (MLST) is used. MLST is a nucleotide sequence-based approach to characterizing bacterial strains [10] . It involves the DNA sequencing of internal fragments of 7 housekeeping genes from the pneumococcal genome. The sequences are compared with previously identified sequences (alleles) and assigned an allele number for each of the 7 loci. The 7 number combinations denote an allelic profile of the strain that is then assigned a sequence type (ST) designation. Sequence types are grouped into ''clonal complexes.'' To be part of clonal complex, members must have typically 5 or 6 loci that match. Interestingly and importantly, isolates with different serotypes can be members of the same clonal complex. Detailed information regarding S. pneumoniae MLST analysis is provided on the pneumococcal MLST website, hosted by Imperial College, London (http://spneumoniae.mlst. net/). The information provided by MLST is global in scope but more in-depth than the serotype designation.
In 
OTHER SERO19A CLONAL COMPLEXES
Whereas CC199, CC320/271, and CC695 comprise most sero19A strains circulating in the United States, other clonal complex variants are present, and of these, many are first documented in the article by Beall et al [11] . What is perhaps most interesting about these new sero19A sequence types is that MLST showed many of them were documented in serotypes other than sero19A. As Beall and coauthors suggest, these data point to a number of serotype switching events having occurred within the last few years. Considering the plasticity of the pneumococcal genome, this change may be not that unusual, and we should expect to find more of these variants in subsequent surveys. As mentioned, the proportion of invasive pneumococcal disease caused by sero19A strains seems to have stabilized in the population surveyed by the ABC program. However, the proportions of the different clonal complexes that comprise the circulating sero19A in the United States have not remained stable. Removal of these vaccine serotypes has possibly provided niches for other serotypes to occupy, such as those that make up the sero19A clonal complexes. Antimicrobial nonsusceptibility also likely plays a role, as antimicrobial-resistant clonal complexes are increasing in prevalence in each year surveyed. Whether these factors are the only drivers for clonal complex sero19A fluctuations is not clear now.
The surveillance program of the ABC group in the United States, coupled with the detailed MLST laboratory analysis of pneumococcal isolates, allows us to identify and track pneumococcal strains that have increased in prevalence following PCV7 introduction. Although sero19A strains now cause a substantial amount of invasive pneumococcal disease and are becoming increasingly resistant to antimicrobials, making these isolates more difficult to treat, a new tool has recently become available to prevent these events from occurring. A proteinconjugate vaccine targeting 13 pneumococcal serotypes (PCV13; PCV7 serotypes plus 1, 3, 5, 6A, 7F, and 19A) will replace PCV7 and should prove as effective as the current conjugate vaccine. With the introduction of the PCV13 vaccine, invasive pneumococcal disease and the antibiotic resistance associated with the sero19A should decline to levels currently seen with the PCV7 serotypes, especially in children for whom the PCV13 vaccine will be targeted. However, as evidenced by the work described by Beall et al and by others, there is a possibility that S. pneumoniae will simply switch its serotype to escape the effects of the PCV13 vaccine. Should this switch occur (and based on evidence in the past decade, it most likely will), we will need to focus efforts on targets other than the capsule as potential pneumococcal vaccine candidates.
